|

Ex-vivo expanded allogeneic γδ T cells Clinical Trials

1 actively recruiting trial

Pipeline

Early 1: 1

Top Sponsors

  • Institute of Hematology & Blood Diseases Hospital, China1

Indications

  • Aml1
  • AML (Acute Myelogenous Leukemia)1
  • Cancer1

Other1 trial

The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.